GlassScriptPhysician profile
Frederick Nicholas Day
NPI 1275736340
$83,402.01
in general payments reported to CMS, 2019-2025
15 companies · $7,419 in 2025
The $7,419 reported for 2025 was more than what 95% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,190 · 2021: $21K · 2022: $14K · 2023: $13K · 2024: $11K · 2025: $7,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Honoraria: $9,900 · Travel and Lodging: $5,990 · Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,600.00 |
| Honoraria | $9,900.00 |
| Travel and Lodging | $5,989.52 |
| Food and Beverage | $2,015.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63,425.96 | 2019-2023 | Krystexxa |
| Amgen INC. | $15,766.99 | 2024-2025 | Krystexxa |
| Stryker Corporation | $3,413.32 | 2019-2024 | Hoffmann, Ortholoc 3di, Prostep Mica |
| Organogenesis INC. | $155.34 | 2024-2025 | Via Matrix, Cygnus Dual, Puraply Am |
| Acumed LLC | $140.03 | 2019 | |
| Paratek Pharmaceuticals, INC. | $110.94 | 2024 | Nuzyra |
| Sobi, INC | $110.27 | 2025 | |
| Trilliant Surgical LLC. | $81.32 | 2019 | |
| Smith+Nephew, INC. | $60.77 | 2019 | |
| Treace Medical Concepts, INC. | $44.47 | 2023-2024 | |
| Dexcom, INC. | $27.31 | 2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.89 | 2025 | Caplyta |
| Acell, INC. | $17.11 | 2019 | |
| Merck Sharp & Dohme LLC | $13.26 | 2019 | |
| Zyla Life Sciences, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.